US
US Allergy Immunotherapy Market Industry Trends and Forecast to 2034: Segmented by (Type, Allergen, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
US · 2024–2034 · estimates
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
US (this report) at $1.04 Bn.
Canada at 8.1% a year.Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$732.4 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $980.7 Mn | — | — |
| 2025 (base) | $1.04 Bn | +$59.8 Mn | — |
| 2026 (forecast) | $1.10 Bn | +$63.5 Mn | +6.1% |
| 2027 (forecast) | $1.17 Bn | +$67.3 Mn | +12.6% |
| 2028 (forecast) | $1.24 Bn | +$71.5 Mn | +19.4% |
| 2029 (forecast) | $1.32 Bn | +$75.8 Mn | +26.7% |
| 2030 (forecast) | $1.40 Bn | +$80.4 Mn | +34.5% |
| 2031 (forecast) | $1.48 Bn | +$85.3 Mn | +42.7% |
| 2032 (forecast) | $1.57 Bn | +$90.5 Mn | +51.4% |
| 2033 (forecast) | $1.67 Bn | +$96.1 Mn | +60.6% |
| 2034 (forecast) | $1.77 Bn | +$101.9 Mn | +70.4% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
US (this report)
$1.04 Bn
China
$199.5 Mn
Canada
$162.4 Mn
Japan
$136.4 Mn
Germany
$74.3 Mn
France
$67.2 Mn
UK
$59.9 Mn
Italy
$53.2 Mn
Spain
$50.5 Mn
Brazil
$51.4 Mn
Ecuador
$50.0 Mn
Saudi Arabia
$47.2 Mn
India
$41.0 Mn
Mexico
$31.0 Mn
Australia
$28.9 Mn
Russia
$21.4 Mn
New Zealand
$21.1 Mn
South Africa
$14.5 Mn
UAE
$10.9 Mn
Egypt
$6.4 Mn
Philippines
$5.3 Mn
Malaysia
$3.7 Mn
Hong Kong
$3.6 Mn
Thailand
$3.2 Mn
Singapore
$2.6 Mn
Kenya
$1.8 Mn
Allergy immunotherapy gradually trains the immune system to tolerate allergens, using shots, tablets or drops.
Key segments of the allergy Immunotherapy market include type (Subcutaneous Immunotherapy, Sublingual Tablets and Sublingual Drops) and allergen (Pollen, Dust Mites and Food).
More people diagnosed with immune diseases, strong results from biologics and oral targeted drugs, and earlier treatment are driving the allergy Immunotherapy market. Biosimilars are widening access.
New targets, oral drugs that replace injections and cell therapies for autoimmune disease give the allergy Immunotherapy market room to grow.
High prices, infection risks with immune-suppressing drugs, patent expiries and the need for long-term treatment hold back the allergy Immunotherapy market.
The allergy Immunotherapy market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for allergy Immunotherapy. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
What doctors and scientists are doing in Allergy Immunotherapy right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
From our blog
Medical Devices · US
Medical Devices · US
Healthcare Services · US
Healthcare Services · US
Medical Devices · US
Healthcare Services · US